VBI Vaccines Inc. (VBIV) Earns Buy Rating from Analysts at Laidlaw
Stock analysts at Laidlaw began coverage on shares of VBI Vaccines Inc. (NASDAQ:VBIV) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating and a $6.00 price target on the biopharmaceutical company’s stock. Laidlaw’s price objective points to a potential upside of 88.09% from the stock’s previous close.
Separately, Ladenburg Thalmann started coverage on shares of VBI Vaccines in a research report on Tuesday, July 26th. They issued a “buy” rating on the stock.
Shares of VBI Vaccines (NASDAQ:VBIV) opened at 3.19 on Monday. VBI Vaccines has a 12-month low of $3.07 and a 12-month high of $4.40. The company’s 50-day moving average is $3.70 and its 200-day moving average is $3.83. The stock’s market cap is $115.26 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/vbi-vaccines-inc-vbiv-earns-buy-rating-from-analysts-at-laidlaw.html
A hedge fund recently raised its stake in VBI Vaccines stock. BlackRock Fund Advisors boosted its position in VBI Vaccines Inc. (NASDAQ:VBIV) by 1,701.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 44,789 shares of the biopharmaceutical company’s stock after buying an additional 42,303 shares during the period. BlackRock Fund Advisors owned about 0.14% of VBI Vaccines worth $177,000 at the end of the most recent quarter. 12.26% of the stock is currently owned by hedge funds and other institutional investors.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.